APTOF
Price
$3.00
Change
+$0.40 (+15.38%)
Updated
Apr 4 closing price
Capitalization
8.62M
MDGL
Price
$310.25
Change
-$4.14 (-1.32%)
Updated
Apr 7, 04:59 PM (EDT)
Capitalization
6.94B
36 days until earnings call
Ad is loading...

APTOF vs MDGL

Header iconAPTOF vs MDGL Comparison
Open Charts APTOF vs MDGLBanner chart's image
Aptose Biosciences
Price$3.00
Change+$0.40 (+15.38%)
Volume$22.82K
Capitalization8.62M
Madrigal Pharmaceuticals
Price$310.25
Change-$4.14 (-1.32%)
Volume$4.05K
Capitalization6.94B
APTOF vs MDGL Comparison Chart
Loading...
APTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APTOF vs. MDGL commentary
Apr 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APTOF is a StrongBuy and MDGL is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 08, 2025
Stock price -- (APTOF: $3.00 vs. MDGL: $314.39)
Brand notoriety: APTOF and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APTOF: 0% vs. MDGL: 94%
Market capitalization -- APTOF: $8.62M vs. MDGL: $6.94B
APTOF [@Biotechnology] is valued at $8.62M. MDGL’s [@Biotechnology] market capitalization is $6.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APTOF’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • APTOF’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than APTOF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APTOF’s TA Score shows that 6 TA indicator(s) are bullish while MDGL’s TA Score has 2 bullish TA indicator(s).

  • APTOF’s TA Score: 6 bullish, 3 bearish.
  • MDGL’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, APTOF is a better buy in the short-term than MDGL.

Price Growth

APTOF (@Biotechnology) experienced а -9.64% price change this week, while MDGL (@Biotechnology) price change was -4.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.36%. For the same industry, the average monthly price growth was -17.88%, and the average quarterly price growth was -17.48%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-9.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.94B) has a higher market cap than APTOF($8.62M). APTOF YTD gains are higher at: 1231.558 vs. MDGL (1.886). APTOF has higher annual earnings (EBITDA): -24.82M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. APTOF (3.32M). APTOF has less debt than MDGL: APTOF (10.7M) vs MDGL (120M). MDGL has higher revenues than APTOF: MDGL (180M) vs APTOF (0).
APTOFMDGLAPTOF / MDGL
Capitalization8.62M6.94B0%
EBITDA-24.82M-450.12M6%
Gain YTD1231.5581.88665,296%
P/E RatioN/AN/A-
Revenue0180M-
Total Cash3.32M926M0%
Total Debt10.7M120M9%
FUNDAMENTALS RATINGS
APTOF vs MDGL: Fundamental Ratings
APTOF
MDGL
OUTLOOK RATING
1..100
1250
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
10026
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
3442
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (69) in the Pharmaceuticals Other industry is in the same range as APTOF (90) in the Biotechnology industry. This means that MDGL’s stock grew similarly to APTOF’s over the last 12 months.

MDGL's Profit vs Risk Rating (26) in the Pharmaceuticals Other industry is significantly better than the same rating for APTOF (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than APTOF’s over the last 12 months.

MDGL's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as APTOF (99) in the Biotechnology industry. This means that MDGL’s stock grew similarly to APTOF’s over the last 12 months.

APTOF's Price Growth Rating (34) in the Biotechnology industry is in the same range as MDGL (42) in the Pharmaceuticals Other industry. This means that APTOF’s stock grew similarly to MDGL’s over the last 12 months.

APTOF's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that APTOF’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APTOFMDGL
RSI
ODDS (%)
Bullish Trend 4 days ago
76%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
65%
Bearish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 15 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
80%
Aroon
ODDS (%)
Bullish Trend 4 days ago
67%
N/A
View a ticker or compare two or three
Ad is loading...
APTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EUSB43.560.05
+0.11%
iShares ESG Advanced Ttl USD Bd Mrkt ETF
FTXH26.59N/A
N/A
First Trust Nasdaq Pharmaceuticals ETF
VWOB62.89-0.77
-1.21%
Vanguard Emerging Mkts Govt Bd ETF
AEF4.64-0.28
-5.60%
abrdn Emerging Markets ex-China Fund Inc.
IMOM25.23-2.45
-8.85%
Alpha Architect Intl Quant Momt ETF

APTOF and

Correlation & Price change

A.I.dvisor tells us that APTOF and BDTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APTOF and BDTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APTOF
1D Price
Change %
APTOF100%
+15.38%
BDTX - APTOF
30%
Poorly correlated
-7.28%
LOGC - APTOF
28%
Poorly correlated
-6.17%
MDGL - APTOF
28%
Poorly correlated
-3.89%
SLNO - APTOF
28%
Poorly correlated
-6.49%
HUMA - APTOF
27%
Poorly correlated
-6.90%
More